Ποια είναι η τιμή για Philogen S.p.A. (PHIL)

Η τιμή για Philogen S.p.A. (PHIL) είναι $27.76

Ποια είναι η κεφαλαιοποίηση αγοράς για Philogen S.p.A. (PHIL)

Η κεφαλαιοποίηση αγοράς για Philogen S.p.A. (PHIL) είναι $801.60M

Philogen S.p.A. (PHIL) Τιμή και Κεφαλαιοποίηση Αγοράς

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.

Η τιμή για PHIL	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$182,266 $801.60M	NVDA	$5.264T	+656,573.47%
$162,786 $801.60M	AAPL	$4.701T	+586,389.50%
$144,639 $801.60M	GOOG	$4.177T	+521,007.66%
$132,181 $801.60M	MSFT	$3.817T	+476,125.12%
$99,249.68 $801.60M	AMZN	$2.866T	+357,478.77%

Η τιμή για PHIL

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$182,266 $801.60M